Clinical Trials Browser

Phase 2 × efgartigimod alfa × Clear all

NCT02965573 2024-08-28

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Phase 2 Completed

24 enrolled 28 charts

Myasthenia Gravis